GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

IX Biopharma 42C.SI · SGD

Health Care · SGX · 🇸🇬 Singapore

Compare

0.45

-4.26%

Close of 6 Nov 2026, in SGD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SGD, from our data supplier.

FY2026

Revenue

SGD 6.9m

FY2017FY2026

Net income

−SGD 8.0m

FY2017FY2026

Free cash flow

−SGD 7.6m

FY2017FY2026

Shareholders' equity

SGD 15.4m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueSGD 6.9mSGD 7.8mSGD 6.0mSGD 5.9mSGD 14.4mSGD 1.7mSGD 985,000SGD 671,000SGD 246,000SGD 6.4m
Research and developmentSGD 2.5mSGD 1.6mSGD 1.7mSGD 2.8mSGD 2.3mSGD 2.7mSGD 2.5mSGD 3.8mSGD 8.0mSGD 4.8m
Operating income−SGD 9.5m−SGD 6.3m−SGD 9.5m−SGD 9.5mSGD 541,000−SGD 11.4m−SGD 11.2m−SGD 13.2m−SGD 15.7m−SGD 10.5m
Net income−SGD 8.0m−SGD 10.1m−SGD 10.8m−SGD 9.6m−SGD 4.6m−SGD 8.2m−SGD 10.5m−SGD 3.0m−SGD 15.1m−SGD 7.4m
Diluted earnings per share-0.01-0.01-0.01-0.01-0.00-0.01-0.02-0.00-0.02-0.01

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsSGD 25.9mSGD 11.3mSGD 14.6mSGD 24.9mSGD 28.5mSGD 18.9mSGD 17.0mSGD 26.7mSGD 33.1mSGD 44.3m
Cash and short-term investments——————SGD 5.7mSGD 15.9mSGD 21.1mSGD 31.1m
Total liabilitiesSGD 10.5mSGD 10.9mSGD 10.3mSGD 9.1mSGD 8.8mSGD 7.1mSGD 6.8mSGD 6.2mSGD 11.6mSGD 8.6m
DebtSGD 120,000SGD 1.5mSGD 2.2mSGD 568,000SGD 876,000SGD 3.2mSGD 3.5mSGD 3.8mSGD 4.5mSGD 4.8m
Shareholders' equitySGD 15.4mSGD 365,000SGD 4.3mSGD 15.9mSGD 19.7mSGD 11.7mSGD 10.2mSGD 20.5mSGD 21.5mSGD 35.6m
Shares outstanding1,068m1,068m1,068m1,068m1,068m697m697m649m643m647m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−SGD 7.5m−SGD 3.8m−SGD 6.6m−SGD 7.7mSGD 3.1m−SGD 8.4m−SGD 8.3m−SGD 13.9m−SGD 8.4m−SGD 4.2m
Capital spending−SGD 117,000−SGD 201,000−SGD 285,000−SGD 695,000−SGD 200,000−SGD 553,000−SGD 984,000−SGD 1.5m−SGD 1.1m−SGD 967,000
Free cash flow−SGD 7.6m−SGD 4.0m−SGD 6.8m−SGD 8.4mSGD 2.9m−SGD 8.9m−SGD 9.3m−SGD 15.4m−SGD 9.5m−SGD 5.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024Jun 2024Dec 2023
RevenueSGD 2.1mSGD 1.6mSGD 3.2mSGD 2.2mSGD 1.8mSGD 3.7mSGD 3.3mSGD 2.7m
Operating income−SGD 4.9m−SGD 751,000−SGD 2.9m−SGD 1.6m−SGD 2.1m−SGD 3.3m−SGD 3.8m−SGD 3.1m
Net income−SGD 5.0m−SGD 916,000−SGD 2.1m−SGD 1.7m−SGD 2.2m−SGD 6.3m−SGD 3.5m−SGD 7.3m
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.01-0.00-0.01
Cash from operations−SGD 2.0m−SGD 2.0m——————
Total assetsSGD 25.9mSGD 27.4mSGD 15.9mSGD 11.3m—SGD 13.1mSGD 14.6mSGD 18.3m
DebtSGD 120,000SGD 1.3mSGD 3.2mSGD 1.5m—SGD 1.8mSGD 2.2mSGD 2.6m
Shareholders' equitySGD 15.4mSGD 17.0mSGD 4.1mSGD 365,000—SGD 3.5mSGD 4.3mSGD 7.7m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.0%31.5%1.7%
Operating income-0.1%-3.6%2.0%
Net income-6.0%-0.6%0.4%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-108.0%-131.6%-107.4%-183.5%
Net margin-124.0%-145.5%-120.5%-167.6%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-62.8-14.3-2.5-5.0-30.0-16.6-16.4-48.2-7.5-18.2
Price to sales73.318.74.58.19.678.3174.7215.0459.821.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.